Labcorp Holdings Inc. LH

Labcorp Holdings Inc. (LH), a North Carolina-based global provider of lab services, diagnostics, and biopharma solutions, remains a large-cap player with about $25.3B market value. Shares have slid 8.9% from a 52-week high of $341.80 (Aug. 27) but advanced 3 months by 22.5%, ahead of the Dow's modest gains. Year-to-date, LH is up about 24.2%, with 52-week gains near 11.7%, and it has traded above its 50- and 200-day moving averages since late June. In Q2 2026, revenue rose 5.8% to $3.7B and adjusted EPS climbed 14.9% to $4.99. Management bumped full-year guidance to 5.4%-6.3% revenue growth and $18.10-$18.55 for adjusted EPS. At Investor Day, Labcorp reiterated 2029 targets of 5%-8% revenue growth and 8.5%-11.5% EPS growth, supported by specialty diagnostics and biopharma services. Analysts remain bullish, with a consensus Strong Buy and a mean target of $348.24. Raised 2026 guidance and outlined 5%-8% revenue growth and 8.5%-11.5% EPS growth through 2029, signaling a stronger long-term trajectory.

Quest Diagnostics and Labcorp shares fell in Tuesday premarket trading after Medicare signaled cuts in payment rates for lab services, heightening concerns about near-term profitability amid reimbursement pressure. Lower Medicare lab-payment rates could materially dent Labcorp's near-term margins.

Labcorp stock fell about 3.3% intraday after CMS disclosed it has been reimbursing lab work at roughly 16% higher rates than private insurers. CMS will cut lab-cost reimbursements by up to 15% starting Jan. 1, 2027. Labcorp derived about 8% of its 2025 revenue from CMS/Medicare/Medicaid. A 15% cut on that 8% translates to about a 1.2% hit to annual revenue, with possible further 15% cuts through 2029 potentially bringing total worst-case revenue impact near 3.6%. The move is priced in to some extent; Motley Fool notes Labcorp wasn't among its top stock picks. The company’s 2025 10-K warned CMS changes could materially affect revenue, profitability, and cash flow. CMS cuts could reduce Labcorp's revenue by up to about 3.6% from 2027–2029, a moderate impact.

Labcorp Holdings plans major investments in AI and specialty testing to drive growth through 2029. Strategic AI and specialty testing investments represent major moves likely to reshape competitive positioning and long-term growth.

Labcorp Holdings Inc. outlined strategic priorities at its 2026 Investor Day to support durable growth and increased shareholder value. Strategic priorities presentation at investor day signals moderate long-term effects on growth and performance.

Labcorp acquires MLM Medical Labs to expand global central laboratory services and biomarker capabilities for clinical trials. Acquisition adds strategic central lab and biomarker capacity that can materially strengthen Labcorp's clinical trial offerings and competitive position.

Labcorp Holdings Inc. launches next generation of Labcorp Global Trial Connect to assist sponsors and investigator sites with clinical trial complexity. Platform upgrade targets core clinical trial services with potential efficiency gains but no evidence of broad financial or market disruption.

Labcorp Holdings (LH) introduced the first FDA-cleared single biomarker blood test for Alzheimer’s disease. Pioneering FDA-cleared Alzheimer’s blood test strengthens Labcorp’s diagnostics leadership and opens new revenue streams in neurological testing.

Labcorp Holdings will offer the first FDA-cleared blood test detecting Alzheimer's disease pathology, available in both primary and specialty care settings. Launch of first FDA-cleared Alzheimer's blood test expands Labcorp's diagnostics reach into primary care and a major new market.

Labcorp Holdings Inc. Q4 earnings met estimates as revenues surpassed projections, driving a rise in the company's stock price. Q4 results meeting estimates with revenue outperformance generated noticeable short-term gains in Labcorp Holdings Inc. stock.

Labcorp Holdings (LH) secured oncology approvals and raised its outlook, prompting assessment of whether the stock is fully priced. Oncology approvals and raised outlook signal major positive developments for Labcorp's performance.

Labcorp Holdings issued stronger financial guidance, announced share buybacks, and launched new oncology tests, developments that may positively shift its investment narrative. Stronger guidance, buybacks and new oncology tests represent strategic growth moves likely to materially improve outlook and investor sentiment.

Labcorp Holdings Inc. receives FDA approval for a companion diagnostic test supporting advanced melanoma patients. FDA approval expands Labcorp oncology diagnostics offerings with potential revenue upside in precision medicine.

Labcorp Holdings Inc. (LH) stock rose 14% over the past month on growth momentum despite rich valuation. Stock gains reflect growth but rich valuation caps upside potential without altering core trajectory.

Labcorp Holdings Inc. launches FDA-approved PTEN companion diagnostic test for prostate cancer. New FDA-approved diagnostic expands Labcorp oncology testing offerings and supports targeted therapies.

Labcorp Holdings Inc. held its Q2 2026 earnings call, covering quarterly financial results, operational performance, and forward guidance for the diagnostic services business. Quarterly earnings data and guidance directly inform near-term valuation and trading activity but rarely reshape long-term strategy.

Quest Diagnostics raised its 2026 outlook as testing demand accelerates. Competitor outlook raise on demand growth signals moderate sector tailwinds for Labcorp.

Labcorp Holdings Inc. launches a marker genetic health panel for consumer testing. Launch of new consumer genetic testing panel represents significant product expansion with potential to boost revenue and market position.

Labcorp Holdings Inc. raised its guidance after Q2 results showed strength in specialty testing and consumer growth. Guidance raise tied to core growth areas signals stronger future results and market response.

Labcorp Holdings Inc. released Q2 earnings call highlights covering financial results, operational updates and outlook. Quarterly earnings updates provide performance details that can shift near-term sentiment but rarely reshape core strategy.

Labcorp Holdings Inc (LH) posted strong revenue growth for Q2 2026 and raised guidance. Strong revenue growth and raised guidance indicate major positive shifts in financial trajectory and investor outlook.

Labcorp Holdings Inc. announced second quarter 2026 results and raised full year 2026 guidance. Earnings beat and raised annual guidance signal stronger expected financial performance.

Labcorp Holdings Inc. released its Q2 2026 earnings call summary covering financial results and operational updates. Quarterly earnings calls typically influence short-term stock sentiment without major strategic shifts.

Labcorp Holdings Inc. (LH) released its Q2 2026 earnings call transcript detailing quarterly financial results, operational updates, and management commentary on performance and outlook. Quarterly earnings calls deliver financial results and guidance that can shift short-term stock sentiment without fundamentally redefining long-term strategy.

Quest Diagnostics identifies multiple growth drivers for 2026, including expanded testing services, technological upgrades, and market expansion strategies that could reshape competitive positioning against peers like Labcorp Holdings. Quest growth plans may exert moderate competitive pressure on Labcorp market share and margins without directly altering its core trajectory.

Labcorp Holdings Inc. released Q2 earnings results with analysis centered on key financial metrics performance. Q2 earnings metrics offer moderate insight into financial trends without indicating transformative shifts.

Labcorp Holdings Inc. prepares to report Q2 earnings, with analysis stressing factors beyond headline estimates that may shape investor understanding of results and outlook. Earnings preview details can moderately sway short-term sentiment and expectations around Labcorp's financial trajectory.

Labcorp launches Marker by Labcorp Genetic Health Panel to expand consumer access to hereditary genetic risk testing. New genetic health panel expands consumer testing access with moderate effects on product offerings and competitive position.

Labcorp Holdings Inc. prepares to report Q2 earnings with focus on expected revenue, profitability and operational metrics that will shape near-term investor views. Earnings previews set expectations that can moderately shift short-term sentiment and valuation without altering long-term strategy.

Labcorp (LH) shares rise 6.1% after FDA approval and Medicare coverage for ColoSense at-home colorectal cancer test. FDA approval plus Medicare coverage for new ColoSense test supports revenue growth in Labcorp diagnostics segment.